New treatment option for Chronic Urticaria - Omalizumab
By Compass Immunology, Sep 17 2017 07:06AM
Omalizumab (Xolair) has recently been listed on the PBS for the treatment of Chronic Spontaneous Urticaria for patients with illness refractory to first line therapies. Chronic urticaria may be a severe illness with significant impact on quality of life. Omalizumab can be very beneficial in patients refractory to standard therapy. Further information is available at:
If you feel this medication may be of benefit to you please discuss with your General Practitioner to see if a referral to our Specialist care would assist you.